Jazz Pharmaceuticals plc (JAZZ) Q3 2026 Earnings Call Transcript
Company Participants
John Bluth – Head of Investor Relations
Renée Galá – President, CEO & Director
Samantha Pearce – Executive VP & Chief Commercial Officer
Robert Iannone – Executive VP, Chief Medical Officer and Global Head of Research & Development
Philip Johnson – Executive VP & CFO
Conference Call Participants
Jessica Fye – JPMorgan Chase & Co, Research Division
Joseph Thome – TD Cowen, Research Division
Andrea Tan – Goldman Sachs Group, Inc., Research Division
Ashwani Verma – UBS Investment Bank, Research Division
William Zhang – Wells Fargo Securities, LLC, Research Division
Marc Goodman – Leerink Partners LLC, Research Division
Chi Meng Fong – BofA Securities, Research Division
Gregory Renza – Truist Securities, Inc., Research Division
Michael Riad – Morgan Stanley, Research Division
Etzer Darout – Barclays Bank PLC, Research Division
Leonid Timashev – RBC Capital Markets, Research Division
David Hoang – Deutsche Bank AG, Research Division
Annabel Samimy – Stifel, Nicolaus & Company, Incorporated, Research Division
David Amsellem – Piper Sandler & Co., Research Division
Ami Fadia – Needham & Company, LLC, Research Division
Presentation
Operator
Ladies and gentlemen, thank you for standing by. Welcome to Jazz Pharmaceuticals 2026 Third Quarter Earnings Call. [Operator Instructions] Please be advised that today’s conference is being recorded. I would like now to turn the conference over to John Bluth, Head of Investor Relations. Please go ahead.
John Bluth
Head of Investor Relations
Thank you, and good afternoon, everyone. Today, Jazz Pharmaceuticals reported its third quarter 2026 financial results. The slide presentation accompanying this webcast is available on the Investors section of our website, along with the press release and quarterly report on Form 10-Q for the quarter ended September 30, 2026.
On the call today are Renee Gala, President and Chief Executive Officer; Sam Pearce, Chief Commercial Officer; Robbie Iannone, Global Head of R&D and Chief Medical Officer; and Phil
